Keratoconus Treatment Options Compared: Conventional Surgery vs Alternative Approaches

Corneal Cross‑Linking (CXL)

Corneal cross‑linking (CXL) is a minimally invasive procedure that creates new covalent bonds between collagen fibrils in the corneal stroma. A photosensitizing solution of riboflavin is applied to the de‑epithelialized or epithelium‑on cornea, then activated with ultraviolet‑A light at a controlled irradiance. The resulting stiffening slows or halts the progressive thinning that characterises keratoconus.

Two main protocols dominate clinical practice. The standard Dresden protocol uses 3 mW/cm² for 30 minutes, delivering 5.4 J/cm², while accelerated regimens increase irradiance to 9–30 mW/cm² and shorten exposure to 3–10 minutes. Both aim to achieve a comparable total fluence, but accelerated versions reduce chair time and may improve patient comfort without compromising biomechanical effect.

Recovery typically spans 3–5 days of epithelial healing, during which a bandage contact lens and topical antibiotics are used. Visual acuity often stabilises within three to six months, and repeat treatment is rare. Complications include transient haze, infection, and, in less than 1 % of cases, corneal melt. Compared with surgical reshaping, CXL preserves native corneal architecture and is usually the first‑line option for progressive disease.

Intrastromal Corneal Ring Segments (ICRS)

Intrastromal corneal ring segments (ICRS) are thin, arc‑shaped polymethyl‑methacrylate implants inserted into a peripheral stromal tunnel created by a femtosecond laser or mechanical dissector. By flattening the central cornea, they reduce irregular astigmatism and improve uncorrected visual acuity. The procedure is reversible; segments can be removed or exchanged if the refractive outcome is unsatisfactory.

Indications include contact‑lens intolerance, mild‑to‑moderate keratoconus with clear central cornea, and a desire to defer transplantation. Typical segment thickness ranges from 150–350 µm, and the arc length is customised to the corneal topography. Post‑operative refractive shift usually stabilises within three months, and many patients achieve spectacle‑level vision without lenses.

Risks comprise segment extrusion, infection, induced higher‑order aberrations, and rare stromal melt. Visual outcomes are less predictable in advanced cones where central scarring limits the flattening effect. When combined with CXL, ICRS can provide both biomechanical stability and immediate refractive improvement, a strategy increasingly adopted in stepwise management algorithms.

Topography‑Guided Photorefractive Keratectomy (TG‑PRK)

Topography‑guided photorefractive keratectomy (TG‑PRK) uses a corneal topographer to map the irregular surface, then directs an excimer laser to ablate tissue in a custom pattern that smooths the cone while preserving as much stromal thickness as possible. The treatment is performed after epithelial removal, often combined with simultaneous CXL to lock in the new shape.

Candidates usually have a minimum residual stromal bed of 350 µm after ablation, stable keratometry for at least six months, and no active ocular surface disease. The algorithm aims to reduce higher‑order aberrations such as coma and trefoil, which are common in keratoconus. Visual recovery is slower than conventional PRK, often requiring three to six months for optimal acuity.

Potential complications include delayed epithelial healing, haze formation, and regression of the refractive effect. Because tissue removal is irreversible, TG‑PRK is generally reserved for eyes that have failed or are unsuitable for CXL and ICRS. Long‑term studies show modest improvement in best‑corrected visual acuity, but the procedure does not halt disease progression on its own.

Corneal Transplantation: Penetrating Keratoplasty (PK) and Deep Anterior Lamellar Keratoplasty (DALK)

Penetrating keratoplasty (PK) replaces the full thickness of the diseased cornea with a donor button, while deep anterior lamellar keratoplasty (DALK) preserves the host endothelium by dissecting the stroma down to Descemet’s membrane. Both restore a regular optical surface and are indicated when corneal scarring, hydrops, or extreme thinning preclude less invasive options.

PK offers the highest graft survival in eyes with endothelial compromise, but carries a lifelong risk of immune rejection, glaucoma, and suture‑related astigmatism. DALK eliminates endothelial rejection because the host endothelium remains intact, yet the technique is technically demanding and may require conversion to PK if a micro‑perforation occurs during the deep stromal dissection.

Visual rehabilitation after transplantation is prolonged; best‑corrected acuity often improves over 12–18 months as sutures are removed and the graft remodels. Post‑operative management includes topical steroids tapered over a year, regular endothelial cell counts, and vigilant monitoring for rejection episodes. In advanced keratoconus, transplantation remains the definitive salvage procedure when all other modalities have been exhausted.

Scleral Contact Lenses

Scleral contact lenses are large‑diameter, gas‑permeable devices that vault the entire corneal surface and rest on the sclera, creating a fluid reservoir that neutralises irregular astigmatism. They provide immediate visual rehabilitation without surgery and are often the first optical correction for moderate to severe keratoconus when spectacles fail.

Fitting requires corneal topography, ocular coherence tomography, and a trial‑lens set to achieve optimal clearance (typically 200–300 µm) and limbal alignment. Modern designs incorporate toric peripheries and fenestrations to improve tear exchange. Patients usually adapt within two weeks, and lens care follows standard rigid‑gas‑permeable protocols.

While scleral lenses do not alter disease biology, they can defer or eliminate the need for surgery in many eyes. Complications include lens‑induced conjunctival compression, microbial keratitis if hygiene lapses, and occasional midday fogging from debris in the reservoir. Regular follow‑ups ensure corneal health and allow timely escalation to CXL or transplantation if progression resumes.

Adjunctive and Homeopathic Approaches

Adjunctive therapies encompass nutritional supplementation (e.g., vitamin B2, omega‑3 fatty acids), low‑level light therapy, and homeopathic preparations that aim to support corneal collagen metabolism. These modalities are not substitutes for evidence‑based interventions but are sometimes used by patients seeking a holistic management plan alongside conventional care.

Homeopathic products for keratoconus typically contain highly diluted substances such as Calcarea fluorica, Silicea, or Natrum muriaticum, selected on the principle of symptom similarity. Clinical trials evaluating these agents are scarce, and existing data do not demonstrate a measurable effect on corneal curvature or biomechanical strength. Practitioners advise that any adjunctive use be disclosed to the treating ophthalmologist.

Safety profiles of homeopathic preparations are generally favorable because the dilution levels render pharmacologically active molecules virtually absent. However, reliance on unproven remedies may delay definitive treatment, especially in progressive disease where timely CXL or transplantation preserves vision. A balanced approach integrates proven medical therapy with patient‑centred supportive care, ensuring informed consent and realistic expectations.